Dysregulated Signaling Pathways in Autism Spectrum Disorder: Molecular Mechanisms, Pharmacological Targets, and Therapeutic Perspectives

Abstract

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by persistent difficulties in social communication and interaction, restricted or repetitive patterns of behavior, and varying degrees of impairment in language, cognition, learning, and adaptive functioning. The etiology of ASD is multifactorial, involving complex interactions between genetic susceptibility and environmental factors. Increasing evidence suggests that genetic variants associated with synaptic development, neuronal connectivity, neurotransmission, and intracellular signaling pathways contribute substantially to ASD pathogenesis. Dysregulation of several molecular signaling networks involved in synaptic plasticity, neuronal differentiation, neurodevelopment, and brain connectivity has also been implicated in the development and progression of ASD. Despite considerable advances in understanding its biological basis, the precise molecular mechanisms underlying ASD remain incompletely elucidated because of its marked genetic and clinical heterogeneity. Consequently, therapeutic management primarily focuses on improving core symptoms, associated behavioral abnormalities, communication, adaptive functioning, and quality of life through individualized behavioral, educational, pharmacological, and supportive interventions. In this review, we critically examine the current evidence regarding molecular and neuronal signaling pathways implicated in ASD, with particular emphasis on their mechanistic roles in disease pathogenesis and their potential as therapeutic targets. We further discuss evidence-based pharmacological and emerging therapeutic strategies associated with these signaling pathways and highlight current knowledge gaps, challenges, and future opportunities for developing mechanism-based interventions for ASD.